These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 31566898)

  • 1. Use of bone-modifying agents and clinical outcomes in older adults with multiple myeloma.
    Olszewski AJ; Barth PM; Reagan JL
    Cancer Med; 2019 Nov; 8(16):6945-6954. PubMed ID: 31566898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subsidies for Oral Chemotherapy and Use of Immunomodulatory Drugs Among Medicare Beneficiaries With Myeloma.
    Olszewski AJ; Dusetzina SB; Eaton CB; Davidoff AJ; Trivedi AN
    J Clin Oncol; 2017 Oct; 35(29):3306-3314. PubMed ID: 28541791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment Patterns and Clinical and Economic Outcomes in Patients With Newly Diagnosed Multiple Myeloma Treated With Lenalidomide- and/or Bortezomib-containing Regimens Without Stem Cell Transplant in a Real-world Setting.
    Chari A; Parikh K; Ni Q; Abouzaid S
    Clin Lymphoma Myeloma Leuk; 2019 Oct; 19(10):645-655. PubMed ID: 31377207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
    Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
    Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment Pattern and Outcomes in Newly Diagnosed Multiple Myeloma Patients Who Did Not Receive Autologous Stem Cell Transplantation: A Real-World Observational Study : Treatment pattern and outcomes in patients with multiple myeloma.
    He J; Schmerold L; Van Rampelbergh R; Qiu L; Potluri R; Dasgupta A; Li L; Li Y; Hu P; Nemat S; Smugar SS; Zeltzer P; Appiani C; Li Q; Mehra M; Richarz U
    Adv Ther; 2021 Jan; 38(1):640-659. PubMed ID: 33211297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bisphosphonates in multiple myeloma: a network meta-analysis.
    Mhaskar R; Redzepovic J; Wheatley K; Clark OA; Miladinovic B; Glasmacher A; Kumar A; Djulbegovic B
    Cochrane Database Syst Rev; 2012 May; (5):CD003188. PubMed ID: 22592688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved survival in Medicare patients with multiple myeloma: findings from a large nationwide and population-based cohort.
    Chen Y; Lairson DR; Chan W; Du XL
    Med Oncol; 2017 Sep; 34(9):153. PubMed ID: 28776319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RNA-seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib/lenalidomide decision signature.
    Chapman MA; Sive J; Ambrose J; Roddie C; Counsell N; Lach A; Abbasian M; Popat R; Cavenagh JD; Oakervee H; Streetly MJ; Schey S; Koh M; Willis F; Virchis AE; Crowe J; Quinn MF; Cook G; Crawley CR; Pratt G; Cook M; Braganza N; Adedayo T; Smith P; Clifton-Hadley L; Owen RG; Sonneveld P; Keats JJ; Herrero J; Yong K
    Blood; 2018 Nov; 132(20):2154-2165. PubMed ID: 30181174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prescription Drug Coverage and Outcomes of Myeloma Therapy Among Medicare Beneficiaries.
    Olszewski AJ; Dusetzina SB; Trivedi AN; Davidoff AJ
    J Clin Oncol; 2018 Oct; 36(28):2879-2886. PubMed ID: 30113885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis B Reactivation Rate and Fate Among Multiple Myeloma Patients Receiving Regimens Containing Lenalidomide and/or Bortezomib.
    Ataca Atilla P; Yalçıner M; Atilla E; İdilman R; Beksaç M
    Turk J Haematol; 2019 Nov; 36(4):266-273. PubMed ID: 31368290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.
    Durie BGM; Hoering A; Abidi MH; Rajkumar SV; Epstein J; Kahanic SP; Thakuri M; Reu F; Reynolds CM; Sexton R; Orlowski RZ; Barlogie B; Dispenzieri A
    Lancet; 2017 Feb; 389(10068):519-527. PubMed ID: 28017406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Second primary malignancy among older adults with multiple myeloma receiving first-line lenalidomide-based therapy: A population-based analysis.
    Giri S; Barth P; Costa LJ; Olszewski AJ
    J Geriatr Oncol; 2021 Mar; 12(2):256-261. PubMed ID: 32684352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bortezomib, cyclophosphamide, dexamethasone versus lenalidomide, cyclophosphamide, dexamethasone in multiple myeloma patients at first relapse.
    Montefusco V; Corso A; Galli M; Ardoino I; Pezzatti S; Carniti C; Patriarca F; Gherlinzoni F; Zambello R; Sammassimo S; Marcatti M; Nozza A; Crippa C; Cafro AM; Baldini L; Corradini P
    Br J Haematol; 2020 Mar; 188(6):907-917. PubMed ID: 31898319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial.
    Manasanch EE; Shah JJ; Lee HC; Weber DM; Thomas SK; Amini B; Feng L; Berkova Z; Hildebrandt M; Orlowski RZ
    Lancet Haematol; 2018 Dec; 5(12):e628-e640. PubMed ID: 30501870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.
    Richardson PG; Oriol A; Beksac M; Liberati AM; Galli M; Schjesvold F; Lindsay J; Weisel K; White D; Facon T; San Miguel J; Sunami K; O'Gorman P; Sonneveld P; Robak P; Semochkin S; Schey S; Yu X; Doerr T; Bensmaine A; Biyukov T; Peluso T; Zaki M; Anderson K; Dimopoulos M;
    Lancet Oncol; 2019 Jun; 20(6):781-794. PubMed ID: 31097405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients.
    Nooka AK; Joseph NS; Kaufman JL; Heffner LT; Gupta VA; Gleason C; Boise LH; Lonial S
    Cancer; 2019 Sep; 125(17):2991-3000. PubMed ID: 31090928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of Bisphosphonates in Elderly Patients With Newly Diagnosed Multiple Myeloma.
    Leng S; Chen Y; Tsai WY; Bhutani D; Hillyer GC; Lim E; Accordino MK; Wright JD; Hershman DL; Lentzsch S; Neugut AI
    J Natl Compr Canc Netw; 2019 Jan; 17(1):22-28. PubMed ID: 30659126
    [No Abstract]   [Full Text] [Related]  

  • 18. Risk adapted post-transplant maintenance in multiple myeloma.
    Vaxman I; Gertz M
    Expert Rev Hematol; 2019 Feb; 12(2):107-118. PubMed ID: 30696304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of prior bortezomib therapy on the incidence of lenalidomide-induced skin rash in multiple myeloma: a propensity score-matched multi-institutional cohort study.
    Dote S; Ito K; Itakura S; Yasu T; Hira D; Noda S; Yamada S; Kobayashi Y; Terada T
    Leuk Lymphoma; 2019 Dec; 60(12):2975-2981. PubMed ID: 31046497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Racial disparity in utilization of therapeutic modalities among multiple myeloma patients: a SEER-medicare analysis.
    Ailawadhi S; Frank RD; Advani P; Swaika A; Temkit M; Menghani R; Sharma M; Meghji Z; Paulus S; Khera N; Hashmi SK; Paulus A; Kakar TS; Hodge DO; Colibaseanu DT; Vizzini MR; Roy V; Colon-Otero G; Chanan-Khan AA
    Cancer Med; 2017 Dec; 6(12):2876-2885. PubMed ID: 29105343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.